{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,8]],"date-time":"2025-10-08T16:37:42Z","timestamp":1759941462584},"reference-count":32,"publisher":"Japanese Society of Internal Medicine","issue":"18","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Intern. Med."],"published-print":{"date-parts":[[2019,9,15]]},"DOI":"10.2169\/internalmedicine.2708-19","type":"journal-article","created":{"date-parts":[[2019,6,6]],"date-time":"2019-06-06T22:03:43Z","timestamp":1559858623000},"page":"2663-2667","source":"Crossref","is-referenced-by-count":6,"title":["Detection of Anti-mitochondrial Antibodies Accompanied by Drug-induced Hepatic Injury due to Atorvastatin"],"prefix":"10.2169","volume":"58","author":[{"given":"Noriyuki","family":"Kuniyoshi","sequence":"first","affiliation":[{"name":"Department of Gastroenterology, Teikyo University Mizonokuchi Hospital, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroshi","family":"Miyakawa","sequence":"additional","affiliation":[{"name":"Fourth Department of Internal Medicine, Teikyo University Mizonokuchi Hospital, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kotaro","family":"Matsumoto","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Teikyo University Mizonokuchi Hospital, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiromichi","family":"Tsunashima","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Teikyo University Mizonokuchi Hospital, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katsunori","family":"Sekine","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Teikyo University Mizonokuchi Hospital, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takayuki","family":"Tsujikawa","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Teikyo University Mizonokuchi Hospital, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masatoshi","family":"Mabuchi","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Teikyo University Mizonokuchi Hospital, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shinpei","family":"Doi","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Teikyo University Mizonokuchi Hospital, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kentaro","family":"Kikuchi","sequence":"additional","affiliation":[{"name":"Fourth Department of Internal Medicine, Teikyo University Mizonokuchi Hospital, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"962","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1. Selmi C, Ichiki Y, Invernizzi P, Podda M, Gershwin ME. The enigma of primary biliary cirrhosis. Clin Rev Allergy Immunol 28: 73-81, 2005.","DOI":"10.1385\/CRIAI:28:2:073"},{"key":"2","unstructured":"2. Lleo A, Marzorati S, Anaya JM, Gershwin ME. Primary biliary cholangitis: a comprehensive overview. Hepatol Int 11: 485-499, 2017."},{"key":"3","doi-asserted-by":"publisher","unstructured":"3. Selmi C, Bowlus CL, Gershwin ME, Coppel RL. Primary biliary cirrhosis. Lancet 377: 1600-1609, 2011.","DOI":"10.1016\/S0140-6736(10)61965-4"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4. Bowlus CL, Gershwin ME. The diagnosis of primary biliary cirrhosis. Autoimmun Rev 13: 441-444, 2014.","DOI":"10.1016\/j.autrev.2014.01.041"},{"key":"5","unstructured":"5. Leung PS, Wang J, Naiyanetr P, et al. Environment and primary biliary cirrhosis: electrophilic drugs and the induction of AMA. J Autoimmun 41: 79-86, 2013."},{"key":"6","doi-asserted-by":"crossref","unstructured":"6. Wang J, Yang G, Dubrovsky AM, Chio J, Leung PSC. Xenobiotics and loss of tolerance in primary biliary cholangitis. World J Gastroenterol 22: 338-348, 2016.","DOI":"10.3748\/wjg.v22.i1.338"},{"key":"7","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/S0021-9150(99)00294-4","volume":"149","author":"RG Bakker-Arkema","year":"2000","unstructured":"7. Bakker-Arkema RG, Nawrocki JW, Black DM. Safety profile of atorvastatin-treated patients with low LDL-cholesterol levels. Atherosclerosis 149: 123-129, 2000.","journal-title":"Atherosclerosis","ISSN":"http:\/\/id.crossref.org\/issn\/0021-9150","issn-type":"print"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8. Krattri S, Zandman-Goddard G. Statins and autoimmunity. Immunol Res 56: 348-357, 2013.","DOI":"10.1007\/s12026-013-8409-8"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9. Alvarado C\u00e1rdenas M, Mar\u00edn S\u00e1nchez A, Lima Ruiz J. Statins and autoimmunity. Med Clin (Barc) 145: 399-403, 2015.","DOI":"10.1016\/j.medcle.2016.03.005"},{"key":"10","doi-asserted-by":"publisher","unstructured":"10. Miyakawa H, Tanaka A, Kikuchi K, et al. Detection of antimitochondrial autoantibodies in immunofluorescent AMA-negative patients with primary biliary cirrhosis using recombinant autoantigens. Hepatology 34: 243-248, 2001.","DOI":"10.1053\/jhep.2001.26514"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11. Takikawa H, Takamori Y, Kumagi T, et al. Assessment of 287 Japanese cases of drug induced liver injury by the diagnostic scale of the international consensus meeting. Hepatol Res 37: 192-195, 2003.","DOI":"10.1016\/S1386-6346(03)00232-8"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12. Takikawa H, Onji M. A proposal of the diagnostic score of drug-induced liver injury. Hepatol Res 32: 250-251, 2005.","DOI":"10.1016\/j.hepres.2005.05.007"},{"key":"13","unstructured":"13. Tsuneyama K, Baba H, Morimoto Y, Tsunematsu T, Ogawa H. Primary biliary cholangitis: Its pathological characteristics and immunopathological mechanisms. J Med Invest 64: 7-13, 2017."},{"key":"14","unstructured":"14. Teramoto T, Sakuma K, Nakao K, Yamamoto O; ALWAYS study group. Atorvastatin lipid lowering assessment survey in patients with hypercholesterolemia (ALWAYS), Final report. Ther Res 34: 445-481, 2013 (in Japanese)."},{"key":"15","doi-asserted-by":"crossref","unstructured":"15. de Castro ML, Hermo JA, Baz A, de Luaces C, Perez R, Clofent J. Acute cholestatic hepatitis after atorvastatin reintroduction. Gastroenterol Hepatol 29: 21-24, 2006.","DOI":"10.1157\/13083248"},{"key":"16","unstructured":"16. No\u00ebl B. Lupus erythematosus and other autoimmune diseases related to statin therapy: a systematic review. J Eur Acad Dermatol Venereol 21: 17-24, 2007."},{"key":"17","doi-asserted-by":"publisher","unstructured":"17. Graziadei IW, Obermoser GE, Sepp NT, Erhart KH, Vogel W. Drug-induced lupus-like syndrome associated with severe autoimmune hepatitis. Lupus 12: 409-412, 2003.","DOI":"10.1191\/0961203303lu313cr"},{"key":"18","unstructured":"18. Moulis G, B\u00e9n\u00e9 J, Sommet A, Sailler L, Lapeyre-Mestre M, Montastruc JL; French Association of PharmacoVigilance Centres. Statin-induced lupus: a case\/non-case study in a nationwide pharmacovigilance database. Lupus 21: 885-889, 2012."},{"key":"19","doi-asserted-by":"crossref","unstructured":"19. Pelli N, Setti M, Ceppa P, Toncini C, Indiveri F. Autoimmune hepatitis revealed by atorvastatin. Eur J Gastroenterol Hepatol 15: 921-924, 2003.","DOI":"10.1097\/00042737-200308000-00014"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20. Alla V, Abraham J, Siddiqui J, et al. Autoimmune hepatitis triggered by statins. J Clin Gastroenterol 40: 757-761, 2006.","DOI":"10.1097\/00004836-200609000-00018"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21. Mammen AL. Statin-Associated Autoimmune Myopathy. N Engl J Med 374: 664-669, 2016.","DOI":"10.1056\/NEJMra1515161"},{"key":"22","unstructured":"22. Nazir S, Lohani S, Tachamo N, Poudel D, Donato A. Statin-associated autoimmune myopathy: A systematic review of 100 cases. J Clin Rheumatol 23: 149-154, 2017."},{"key":"23","unstructured":"23. Mammen AL, Gaudet D, Brisson D, et al. Increased frequency of DRB1*11:01 in anti-hydroxymethylglutaryl-coenzyme A reductase-associated autoimmune myopathy. Arthritis Care Res (Hoboken) 64: 1233-1237, 2012."},{"key":"24","doi-asserted-by":"crossref","unstructured":"24. Patel J, Superko HR, Martin SS, et al. Genetic and immunologic susceptibility to statin-related myopathy. Atherosclerosis 240: 260-271, 2015.","DOI":"10.1016\/j.atherosclerosis.2015.03.025"},{"key":"25","doi-asserted-by":"crossref","unstructured":"25. Christopher-Stine L, Casciola-Rosen LA, Hong G, et al. A novel autoantibody recognizing 200-kd and 100-kd proteins is associated with an immune-mediated necrotizing myopathy. Arthritis Rheum 62: 2757-2766, 2010.","DOI":"10.1002\/art.27572"},{"key":"26","doi-asserted-by":"crossref","unstructured":"26. Mammen AL, Chang T, Christopher-Stine L, et al. Autoantibodies against 3-hydroxy-3-methylgultaryl-coenzyme A reductase in patients with statin-associated autoimmune myopathy. Arthritis Rheum 63: 713-721, 2011.","DOI":"10.1002\/art.30156"},{"key":"27","doi-asserted-by":"crossref","unstructured":"27. Punthakee Z, Scully LJ, Guindi MM, et al. Liver fibrosis attributed to lipid lowering medications two cases. J Int Med 250: 249-254, 2001.","DOI":"10.1046\/j.1365-2796.2001.00848.x"},{"key":"28","unstructured":"28. Minha Sa'ar, Golzman G, Adar I, Rapoport M. Cholestatic jaundice induced by Atorvastatin: a possible association with antimitochondrial antibodies. Isr Med Assoc J 11: 440-441, 2009."},{"key":"29","doi-asserted-by":"crossref","unstructured":"29. Nakayama S, Murashima N. Overlap syndrome of autoimmune hepatitis and primary biliary cirrhosis triggered by fluvastatin. Indian J Gastroenterol 30: 97-99, 2011.","DOI":"10.1007\/s12664-011-0092-x"},{"key":"30","unstructured":"30. Yanagawa T, Miyakawa H, Shibata M, et al. Immunoreacivity to pyruvate dehydrogenase complex-E2 in well-defined patients with autoimmune hepatitis: western blot analysis. Hepatol Res 26: 81-86, 2013."},{"key":"31","doi-asserted-by":"crossref","unstructured":"31. Klatskin G, Kantor FS. Mitochondrial antibody in primary biliary cirrhosis and other diseases. Ann Intern Med 77: 533-541, 1972.","DOI":"10.7326\/0003-4819-77-4-533"},{"key":"32","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.1002\/hep.21828","volume":"46","author":"PSC Leung","year":"2007","unstructured":"32. Leung PSC, Rossaro L, Davis PA, et al. Antimitochondrial antibodies in acute liver failure: Implications for primary biliary cirrhosis. Hepatology 46: 1436-1442, 2007.","journal-title":"Hepatology","ISSN":"http:\/\/id.crossref.org\/issn\/0270-9139","issn-type":"print"}],"container-title":["Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/58\/18\/58_2708-19\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,9,21]],"date-time":"2019-09-21T03:38:47Z","timestamp":1569037127000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/58\/18\/58_2708-19\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,9,15]]},"references-count":32,"journal-issue":{"issue":"18","published-print":{"date-parts":[[2019]]}},"URL":"https:\/\/doi.org\/10.2169\/internalmedicine.2708-19","relation":{},"ISSN":["0918-2918","1349-7235"],"issn-type":[{"value":"0918-2918","type":"print"},{"value":"1349-7235","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,9,15]]}}}